In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...

Japanese biotech Nxera Pharma (TSE: 4565) has received a $15 million payment from Neurocrine Biosciences (Nasdaq: NBIX) after ...

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone ...

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences ...

(RTTNews) - Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY) targeting diabetes ...

Cambridge UK and Tokyo biopharma business Nxera Pharma has hauled in $15 million after partner Neurocrine Biosciences dosed the first patient in its Phase 3 registrational programme of NBI-1117568 ...

Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has ...

Nxera Pharma Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under ...

Zeit Aktuelle Nachrichten 01:36 Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 Tokyo, Japan and Cambridge, UK ...